Lung Cancer Genomic Testing Medicine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Sample Type, By Panel Type, By End-User, By Region and Competition, 2020-2030F

Description

The Global Lung Cancer Genomic Testing Medicine Market will grow from USD 1.90 Billion in 2024 to USD 2.59 Billion by 2030 at a 5.30% CAGR. Lung cancer genomic testing medicine encompasses the analysis of tumor deoxyribonucleic acid to identify specific genetic mutations or alterations, enabling the selection of personalized therapeutic strategies for patients. The market's growth is primarily driven by the rising global incidence of lung cancer, continuous advancements in genomic sequencing technologies such as Next-Generation Sequencing, and an increasing imperative for precision medicine approaches in oncology.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1.90 Billion
Market Size 2030	USD 2.59 Billion
CAGR 2025-2030	5.30%
Fastest Growing Segment	Polymerase Chain Reaction
Largest Market	North America

Key Market Drivers

The market for global lung cancer genomic testing medicine is significantly influenced by the increasing worldwide incidence of lung cancer. This escalating disease burden creates an urgent demand for advanced diagnostic tools to facilitate precise patient stratification and guide targeted therapeutic interventions. Lung cancer consistently ranks as a leading cause of cancer-related mortality globally, necessitating innovation in diagnostic capabilities.

Key Market Challenges

The substantial cost associated with advanced genomic testing represents a significant impediment to the growth of the Global Lung Cancer Genomic Testing Medicine Market. High test expenses directly limit patient access, particularly in healthcare systems facing budgetary constraints or where comprehensive reimbursement policies are not fully established. This financial barrier can deter clinicians from ordering these essential tests and prevent patients from undergoing molecular profiling, thereby restricting the overall adoption rate of precision medicine strategies in lung cancer.

Key Market Trends

Artificial intelligence and machine learning are significantly enhancing lung cancer genomic interpretation, improving speed and accuracy for complex data analysis. These technologies enable precise identification of actionable mutations crucial for targeted therapies. For instance, the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer showcased an AI tool, DeepGEM, for gene mutation prediction from histopathology slides, with data from 3,658 patients analyzed.

Key Market Players

QIAGEN NV
Agilent Technologies Inc.
Thermo Fisher Scientific Inc.
Quest Diagnostics Incorporated
Laboratory Corporation of America Holdings
CENTOGENE N.V.
BGI Genomics Co. Ltd.
CeGaT GmbH
Illumina Inc.
F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Medicine Market, By Technology:

Polymerase Chain Reaction
Next-Generation Sequencing
Fluorescence In-Situ Hybridization
Others

Lung Cancer Genomic Testing Medicine Market, By Sample Type:

Tissue Biopsy
Liquid Biopsy

Lung Cancer Genomic Testing Medicine Market, By Panel Type:

Multi-Gene Panel
Single-Gene Panel

Lung Cancer Genomic Testing Medicine Market, By End-User:

Research Organization
Hospitals & Clinics
Diagnostic Laboratories
Others

Lung Cancer Genomic Testing Medicine Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Lung Cancer Genomic Testing Medicine Market.

Available Customizations:

Global Lung Cancer Genomic Testing Medicine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Medicine Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Technology (Polymerase Chain Reaction, Next-Generation Sequencing, Fluorescence In-Situ Hybridization, Others)
- 5.2.2. By Sample Type (Tissue Biopsy, Liquid Biopsy)
- 5.2.3. By Panel Type (Multi-Gene Panel, Single-Gene Panel)
- 5.2.4. By End-User (Research Organization, Hospitals & Clinics, Diagnostic Laboratories, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
5.3. Market Map

6. North America Lung Cancer Genomic Testing Medicine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Technology
- 6.2.2. By Sample Type
- 6.2.3. By Panel Type
- 6.2.4. By End-User
- 6.2.5. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Lung Cancer Genomic Testing Medicine Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Technology
    - 6.3.1.2.2. By Sample Type
    - 6.3.1.2.3. By Panel Type
    - 6.3.1.2.4. By End-User
- 6.3.2. Canada Lung Cancer Genomic Testing Medicine Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Technology
    - 6.3.2.2.2. By Sample Type
    - 6.3.2.2.3. By Panel Type
    - 6.3.2.2.4. By End-User
- 6.3.3. Mexico Lung Cancer Genomic Testing Medicine Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Technology
    - 6.3.3.2.2. By Sample Type
    - 6.3.3.2.3. By Panel Type
    - 6.3.3.2.4. By End-User

7. Europe Lung Cancer Genomic Testing Medicine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Technology
- 7.2.2. By Sample Type
- 7.2.3. By Panel Type
- 7.2.4. By End-User
- 7.2.5. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Lung Cancer Genomic Testing Medicine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Technology
    - 7.3.1.2.2. By Sample Type
    - 7.3.1.2.3. By Panel Type
    - 7.3.1.2.4. By End-User
- 7.3.2. France Lung Cancer Genomic Testing Medicine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Technology
    - 7.3.2.2.2. By Sample Type
    - 7.3.2.2.3. By Panel Type
    - 7.3.2.2.4. By End-User
- 7.3.3. United Kingdom Lung Cancer Genomic Testing Medicine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Technology
    - 7.3.3.2.2. By Sample Type
    - 7.3.3.2.3. By Panel Type
    - 7.3.3.2.4. By End-User
- 7.3.4. Italy Lung Cancer Genomic Testing Medicine Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Technology
    - 7.3.4.2.2. By Sample Type
    - 7.3.4.2.3. By Panel Type
    - 7.3.4.2.4. By End-User
- 7.3.5. Spain Lung Cancer Genomic Testing Medicine Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Technology
    - 7.3.5.2.2. By Sample Type
    - 7.3.5.2.3. By Panel Type
    - 7.3.5.2.4. By End-User

8. Asia Pacific Lung Cancer Genomic Testing Medicine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Technology
- 8.2.2. By Sample Type
- 8.2.3. By Panel Type
- 8.2.4. By End-User
- 8.2.5. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Lung Cancer Genomic Testing Medicine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Technology
    - 8.3.1.2.2. By Sample Type
    - 8.3.1.2.3. By Panel Type
    - 8.3.1.2.4. By End-User
- 8.3.2. India Lung Cancer Genomic Testing Medicine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Technology
    - 8.3.2.2.2. By Sample Type
    - 8.3.2.2.3. By Panel Type
    - 8.3.2.2.4. By End-User
- 8.3.3. Japan Lung Cancer Genomic Testing Medicine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Technology
    - 8.3.3.2.2. By Sample Type
    - 8.3.3.2.3. By Panel Type
    - 8.3.3.2.4. By End-User
- 8.3.4. South Korea Lung Cancer Genomic Testing Medicine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Technology
    - 8.3.4.2.2. By Sample Type
    - 8.3.4.2.3. By Panel Type
    - 8.3.4.2.4. By End-User
- 8.3.5. Australia Lung Cancer Genomic Testing Medicine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Technology
    - 8.3.5.2.2. By Sample Type
    - 8.3.5.2.3. By Panel Type
    - 8.3.5.2.4. By End-User

9. Middle East & Africa Lung Cancer Genomic Testing Medicine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Technology
- 9.2.2. By Sample Type
- 9.2.3. By Panel Type
- 9.2.4. By End-User
- 9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Medicine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Technology
    - 9.3.1.2.2. By Sample Type
    - 9.3.1.2.3. By Panel Type
    - 9.3.1.2.4. By End-User
- 9.3.2. UAE Lung Cancer Genomic Testing Medicine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Technology
    - 9.3.2.2.2. By Sample Type
    - 9.3.2.2.3. By Panel Type
    - 9.3.2.2.4. By End-User
- 9.3.3. South Africa Lung Cancer Genomic Testing Medicine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Technology
    - 9.3.3.2.2. By Sample Type
    - 9.3.3.2.3. By Panel Type
    - 9.3.3.2.4. By End-User

10. South America Lung Cancer Genomic Testing Medicine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Technology
- 10.2.2. By Sample Type
- 10.2.3. By Panel Type
- 10.2.4. By End-User
- 10.2.5. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Lung Cancer Genomic Testing Medicine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Technology
    - 10.3.1.2.2. By Sample Type
    - 10.3.1.2.3. By Panel Type
    - 10.3.1.2.4. By End-User
- 10.3.2. Colombia Lung Cancer Genomic Testing Medicine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Technology
    - 10.3.2.2.2. By Sample Type
    - 10.3.2.2.3. By Panel Type
    - 10.3.2.2.4. By End-User
- 10.3.3. Argentina Lung Cancer Genomic Testing Medicine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Technology
    - 10.3.3.2.2. By Sample Type
    - 10.3.3.2.3. By Panel Type
    - 10.3.3.2.4. By End-User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Medicine Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. QIAGEN NV
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. Agilent Technologies Inc.
15.3. Thermo Fisher Scientific Inc.
15.4. Quest Diagnostics Incorporated
15.5. Laboratory Corporation of America Holdings
15.6. CENTOGENE N.V.
15.7. BGI Genomics Co. Ltd.
15.8. CeGaT GmbH
15.9. Illumina Inc.
15.10. F. Hoffmann-La Roche Ltd